[Scoring pharmacodependence seriousness: a novel CEIP's evaluation tool]
Related Experiment Video
Updated: Jul 16, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Caroline Victorri-Vigneau1, Pascale Jolliet
1Centre d'Evaluation et d'Information sur la Pharmacodépendance, Service de Pharmacologie Clinique, CHU Nantes, Nantes, France. caroline.vigneau@chu-nantes.fr
Abstract:
In France, the Afssaps is the body in charge of the evaluation of pharmacodependance. In order to fulfil its mission, the Afssaps has created a network of 10 Centres for Evaluation and Information on Pharmacodependance (CEIP), coordinated by the Drugs and Psychotropics Unit. Pharmacodependence notifications issued by professionals are collected by each Centre which evaluates them: it is therefore necessary to harmonize case reporting and make it possible to homogeneously evaluate the seriousness of pharmacodependence cases. Nantes CEIP has developed and has been routinely using a tool which evaluates pharmacodependence seriousness by quantifying patient consumption behaviour: the corresponding calculation, interpretation related to 3 patients is presented in this article. The association of clinical data generated by the tool, and official data coming from CEIP's, represents a powerful combination which is now available for pharmacodependence and abuse diagnosis.
Related Concept Videos
Quantitative Aspects of Drug-Receptor Interaction
Drug Dependence
Pharmacodynamic Responses: Different Types
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

